219
Participants
Start Date
May 31, 2008
Primary Completion Date
June 30, 2009
Study Completion Date
June 30, 2009
Fostamatinib disodium (R935788)
R935788 100 mg tablet, orally, twice-a-day
Placebo
Placebo, orally, twice-a-day
Instituto de Ginecologia y Reproduccion, Lima
ZNA Middelheim, Antwepen
CHU Liege, Liège
UZ Gent, Ghent
North Shore Long Island Jewich Health System, Lake Success
Andrew Porges, MD PC, Roslyn
Rheumatology Associates of Long Island, Smithtown
Rheumatology Associates, Erie
Rheumatic Disease Associates, Willow Grove
Department of Rheumatology, Washington D.C.
The Osteoporosis & Clinical Trials Center, Cumberland
The Osteoporosis & Clinical Trials Center, Hagerstown
Klinikum Eilbek, Hamburg
Florida Medical Research Institute, Gainsville
Hopital Pellegrin, Bordeaux
Azienda Ospedaliera Santa Maria della Miseri, Udine
Arthritis & Rheumatic Disease Specialties, Aventura
RASF-Clinical Research Center, Boca Raton
Lovelace Scientific Resources, Sarasota
Paddock Park Clinical Research, Ocala
Clinical Research Center of Reading, LLP, West Reading
Center for Arthritis & Osteoperosis, Elizabethtown
Clinical Research Division, Mayfield Village
Memorial Medical Group Clinical Research Inst, South Bend
Fiechtner Research, Inc., Lansing
Reumatologia Azienda Ospedaliera Universitaria, Siena
Klinikum der J.W. Goethe Universitaet, Frankfurt
Rheumatology Associates, SC, Chicago
Westroads Medical Group, Omaha
Health Research of Oklahoma, Oklahoma City
Houston Institute for Clinical Research, Houston
Austin Rheumatology & Research, Austin
Intermountain Orthopedics, Boise
San Diego Arthritis & Medical Clinic, San Diego
Desert Medical Advances, Palm Desert
Universitatsklinikum Wurzburg, Würzburg
Arthritis Northwest, PLLC, Spokane
Reumalab S.A., Medellín
Reumatologos del Caribe, Barranquilla
CIREEM, Bogota
Dr. Renato Guzman, Bogota
Riesgo de Fractura S.A., Bogota
ClinPharm International GmbH Leipzig, Leipzig
Rheumazentrum am Universitatsklinikum Leipzig, Leipzig
Lead Sponsor
Rigel Pharmaceuticals
INDUSTRY